We also revealed that miR‐125b, regulated by C/EBPα transcriptional factor, and its target, GluN2A, are involved in the underlying mechanism for the neuroprotective effect of MT2 activation (Figure 6), which could be a useful treatment for synaptic disorder in AD. This evidence concerns the gene GRIN2A and Alzheimer disease.